Abstract: The present technology is directed to compositions and methods for preventing, ameliorating, or reducing the severity of one or more signs, or symptoms associated with a reduction of function, decreased expression level of, and/or deficiency in one or more of COL4A3, COL4A4 and COL4A5 genes. Also disclosed herein are methods of preventing or treating Alport Syndrome in a mammalian subject, reducing risk factors associated with Alport Syndrome, and/or reducing the likelihood or severity of Alport Syndrome. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide.

Abstract: The present disclosure provides methods of preventing or treating renal ischemia-reperfusion injury in a mammalian subject and methods for chronic treatment of ARVD, including administering an effective amount of an aromatic-cationic peptide to a subject in need thereof. The methods include administering aromatic-cationic peptides to prevent or treat renal injury during the treatment of renal artery stenosis. The methods include administering an effective amount of an aromatic-cationic peptide to subjects in need thereof.

Abstract: The disclosure provides methods of preventing or treating Barth Syndrome in a mammalian subject, reducing risk factors associated with Barth Syndrome, and/or reducing the likelihood or severity of Barth Syndrome. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to increase expression of TAZ1 in subjects in need thereof.

Abstract: The invention provides methods of treating an obstructive coronary artery disease in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof and performing a coronary artery bypass graft procedure on the subject.

Abstract: The present technology provides methods of preventing or treating vitiligo. The methods provide administering aromatic-cationic peptides in effective amounts to treat or ameliorate melanocyte degeneration such as that found in a subject suffering from, or predisposed to vitiligo. In some embodiments, the methods comprise administering to a subject suffering from, or at risk for vitiligo, an effective amount of an aromatic-cationic peptide to subjects in need thereof. The present technology relates to the treatment, amelioration or prevention of vitiligo in mammals or mammalian cells, through administration of therapeutically effective amounts of aromatic-cationic peptides, such as D-Arg-2?,6?-Dmt-Lys-Phe-NH2.

Abstract: A voice command definition file (VCDF) declaratively defines voice commands for an application. For example, the VCDF may include definitions for: voice commands; one or more phrases/utterances that may be said to execute each of the commands; a navigation location to navigate to within the application (e.g. a page); phrase lists containing items that may be used as a parameter in a voice command; examples; feedback; and the like. A user may say a single utterance to launch the application, navigate to the associated location of the command and execute the command. The VCDF may define multiple ways to listen for a particular command. The VCDF may be edited/defined by a user and may include a user friendly name for an application. A speech engine loads the VCDF for use such that it may recognize the commands associated with an application. The definitions may be updated during runtime.

Abstract: Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of mitochondrial fission inhibitor peptides (e.g., P110), and/or naturally or artificially occurring derivatives, analogues, or pharmaceutically acceptable salts thereof (e.g., P110*), alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide). The present technology provides compositions related to aromatic-cationic peptides linked to mitochondrial fission inhibitor peptides and uses of the same. In some embodiments, the aromatic-cationic peptide comprises D-Arg-2?6?-Dmt-Lys-Phe-NH2.

Abstract: The present technology provides methods of generating the peptides, and pharmaceutically acceptable salts of the peptides and intermediates thereof. In some embodiments, the peptide is D-Arg-2?6?-Dmt-Lys-Phe-NH2.

Abstract: The disclosure provides methods of reducing MMP-9 expression and/or MMP-9 activity in a mammalian subject. The disclosure also provides methods of increasing TIMP-1 expression and/or TIMP-1 activity in a mammalian subject. The methods comprise administering a therapeutically effective amount of an aromatic-cationic peptide to a subject in need thereof.

Abstract: The disclosure provides methods and compositions for increasing SERCA2a expression levels in a mammalian subject in need thereof. The methods comprise administering to the subject a therapeutic amount of an aromatic-cationic peptide to subjects in need thereof. In some embodiments, the aromatic-cationic peptide is D-Arg-2?6?-Dmt-Lys-Phe-NH2, or a pharmaceutically acceptable salt thereof such as acetate or trifluoroacetate salt. In some embodiments, the subject has suffered a myocardial infarction.

Abstract: The disclosure relates to methods for treating a subject suffering from hyperalgesia caused by drug-induced neuropathy by administering to the subject an effective amount of an aromatic-cationic peptide. The disclosure also relates to methods for protecting a subject from hyperalgesia caused by drug-induced neuropathy by administering an effective amount of an aromatic-cationic peptide to a subject at risk for developing the condition.

Abstract: The invention provides compositions and methods for preventing or treating an ischemia-reperfusion injury, such as occurs during acute myocardial infarction and organ transplant in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide or a pharmaceutically acceptable salt thereof, and one or more additional active agents such as cyclosporine.

Abstract: The present disclosure provides aromatic-cationic peptide compositions and methods of using the same. The methods comprise use of the peptides in electron transport and electrical conductance.

Abstract: Disclosed herein are compositions and methods related to aromatic-cationic peptides. In particular, the compositions and methods relate to aromatic-cationic peptides in conjunction with cytochrome c.

Abstract: Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of a therapeutic biological molecule, and/or naturally or artificially occurring derivatives, analogues, or pharmaceutically acceptable salts thereof, alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide). The present technology provides compositions related to aromatic-cationic peptides linked to a therapeutic biological molecule and uses of the same. In some embodiments, the aromatic-cationic peptide comprises 2?,6?-dimethyl-Tyr-D-Arg-Phe-Lys-NH2, Phe-D-Arg-Phe-Lys-NH2, or D-Arg-2?,6?-Dmt-Lys-Phe-NH2.

Abstract: Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of TSM, and/or naturally or artificially occurring derivatives, analogues, or pharmaceutically acceptable salts thereof, alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide). The present technology provides compositions related to aromatic-cationic peptides linked to TSM and uses of the same. In some embodiments, the aromatic-cationic peptide comprises 2?,6?-dimethyl-Tyr-D-Arg-Phe-Lys-NH2, Phe-D-Arg-Phe-Lys-NH2, or D-Arg-2?,6?-Dmt-Lys-Phe-NH2.

Abstract: The disclosure provides methods of preventing or treating Barth Syndrome in a mammalian subject, reducing risk factors associated with Barth Syndrome, and/or reducing the likelihood or severity of Barth Syndrome. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to increase expression of TAZ1 in subjects in need thereof.

Abstract: Incorporation of an exogenous large-vocabulary model into rule-based speech recognition is provided. An audio stream is received by a local small-vocabulary rule-based speech recognition system (SVSRS), and is streamed to a large-vocabulary statistically-modeled speech recognition system (LVSRS). The SVSRS and LVSRS perform recognitions of the audio. If a portion of the audio is not recognized by the SVSRS, a rule is triggered that inserts a mark-up in the recognition result. The recognition result is sent to the LVSRS. If a mark-up is detected, recognition of a specified portion of the audio is performed. The LVSRS result is unified with the SVSRS result and sent as a hybrid response back to the SVSRS. If the hybrid-recognition rule is not triggered, an arbitration algorithm is evoked to determine whether the SVSRS or the LVSRS recognition has a lesser word error rate. The determined recognition is sent as a response to the SVSRS.

Abstract: The present technology provides methods for detecting and diagnosing diseases and conditions characterized by mitochondrial dysfunction using monocytes as an indicator of the dysfunction.

Abstract: The disclosure relates to methods for treating a subject suffering from hyperalgesia caused by drug-induced neuropathy by administering to the subject an effective amount of an aromatic-cationic peptide. The disclosure also relates to methods for protecting a subject from hyperalgesia caused by drug-induced neuropathy by administering an effective amount of an aromatic-cationic peptide to a subject at risk for developing the condition.